NYSE:TARO

Taro Pharmaceutical Industries (TARO) Stock Forecast, Price & News

$37.85

-0.47 (-1.23%)

(As of 09/22/2023 ET)

Compare

Today's Range: $37.37
▼
$38.00
50-Day Range: $35.49
▼
$40.13
52-Week Range: $22.89
▼
$42.22

Volume: 19,780 shs
Average Volume: 36,408 shs
Market Capitalization: $1.42 billion

P/E Ratio: 66.40
Dividend Yield: N/A
Price Target: $35.00

Taro Pharmaceutical Industries MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 7.5% Downside
$35.00 Price Target
Short Interest: Bearish
4.93% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.29 out of 5 stars

Medical Sector

933rd out of 968 stocks

Pharmaceutical Preparations Industry

432nd out of 445 stocks

1.5

Analyst's Opinion

Consensus Rating
Taro Pharmaceutical Industries has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $35.00, Taro Pharmaceutical Industries has a forecasted downside of 7.5% from its current price of $37.85.
Amount of Analyst Coverage
Taro Pharmaceutical Industries has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.93% of the float of Taro Pharmaceutical Industries has been sold short.
Short Interest Ratio / Days to Cover
Taro Pharmaceutical Industries has a short interest ratio ("days to cover") of 6.2.
Change versus previous month
Short interest in Taro Pharmaceutical Industries has recently increased by 82.51%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Taro Pharmaceutical Industries does not currently pay a dividend.
Dividend Growth
Taro Pharmaceutical Industries does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TARO.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Taro Pharmaceutical Industries this week, compared to 2 articles on an average week.
MarketBeat Follows
1 people have added Taro Pharmaceutical Industries to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Taro Pharmaceutical Industries insiders have not sold or bought any company stock.
Percentage Held by Insiders
13.80% of the stock of Taro Pharmaceutical Industries is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 11.45% of the stock of Taro Pharmaceutical Industries is held by institutions.

1.9

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Taro Pharmaceutical Industries is 66.40, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 123.93.
Price to Earnings Ratio vs. Sector
The P/E ratio of Taro Pharmaceutical Industries is 66.40, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 127.03.
Price to Book Value per Share Ratio
Taro Pharmaceutical Industries has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Taro Pharmaceutical Industries (NYSE:TARO) Stock

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.

TARO Price History

30 days | 90 days | 365 days | Advanced Chart

TARO Stock News Headlines

September 20, 2023 | americanbankingnews.com

Taro Pharmaceutical Industries (NYSE:TARO) Upgraded to "Strong-Buy" by StockNews.com

August 16, 2023 | seekingalpha.com

Taro Pharmaceutical: Sun Pharma Deal Uncertain, No Discernible Value Beyond NAV (Rating Downgrade)

September 22, 2023 | Chaikin Analytics (Ad)

Wall Street Insider Makes Prediction about Hot A.I. Stock

50-year Wall Street Veteran Marc Chaikin just detailed why he's avoiding NVDA and buying this overlooked A.I. stock instead. Learn more here.

July 31, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Taro Pharmaceutical (TARO), Boston Scientific (BSX)

July 27, 2023 | finance.yahoo.com

Taro Provides Results for the Quarter Ended June 30, 2023

July 19, 2023 | finance.yahoo.com

Krensavage Asset Management Opposes Sun's Lowball Bid for Taro

July 8, 2023 | theglobeandmail.com

Instrument Name Taro Pharm Inds Instrument Symbol (TARO-N)

June 30, 2023 | finance.yahoo.com

Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2023

September 22, 2023 | Chaikin Analytics (Ad)

Wall Street Insider Makes Prediction about Hot A.I. Stock

50-year Wall Street Veteran Marc Chaikin just detailed why he's avoiding NVDA and buying this overlooked A.I. stock instead. Learn more here.

June 2, 2023 | seekingalpha.com

Taro Pharmaceutical: Potential Value In Sun Pharma Offer

June 2, 2023 | msn.com

Sun Pharma's Latest Cash Offer for Taro Might Actually Seal the Deal This Time Around

May 30, 2023 | finance.yahoo.com

Why Shares of Taro Pharmaceutical Are Rising Tuesday

May 30, 2023 | msn.com

HeartBeam, Taro top healthcare gainers; Enveric, Bright Health among losers

May 30, 2023 | marketwatch.com

Taro Pharmaceutical Shares Surge Premarket as Sun Pharma Proposes Buyout >TARO

May 27, 2023 | seekingalpha.com

Taro Pharma weighing offer from Sun Pharma to acquire company at $38 share

May 24, 2023 | msn.com

Taro Pharmaceutical misses top an bottom line consensus for Q1

May 23, 2023 | finance.yahoo.com

Taro Provides Results for Year Ended March 31, 2023

May 23, 2023 | markets.businessinsider.com

What Wall Street expects from Taro Pharmaceutical Industries's earnings

May 16, 2023 | marketwatch.com

2023 to 2030, Hydrocortisone Butyrate Market: Business Strategic and Growth Analysis

May 12, 2023 | marketwatch.com

Nystatin and Triamcinolone Acetonide Market 2023 to Hit Statistical Significance Value by 2030

May 10, 2023 | marketwatch.com

Future of Clindamycin Phosphate Topical Market 2023: Active Key Players and Emerging Trends in Industry till 2030

May 10, 2023 | marketwatch.com

Lice Treatment Market Qualitative and Quantitative Inputs Drive Industry Growth

May 8, 2023 | marketwatch.com

The Takotsubo Syndrome Therapeutics Market Trends: 2023 Segmentation in Customer Targeting

May 3, 2023 | marketwatch.com

Enalapril Market 2023 : Recent Developments, Industry Trends and Investigation Growth Rate, and Forecast to 2031

April 28, 2023 | marketwatch.com

Urticaria Drug Market Business Report [2023-2030]

April 27, 2023 | marketwatch.com

Oxcarbazepine Market Market Trends By 2030

April 20, 2023 | marketwatch.com

Urticaria Drug Market Facts and Figures By 2030

See More Headlines

Receive TARO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taro Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TARO Company Calendar

Last Earnings: 7/26/2023
Today: 9/22/2023
Next Earnings (Estimated): 10/26/2023
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:TARO
CUSIP: N/A
CIK: 906338
Web: www.taro.com
Phone: (724) 847-5700
Fax: 914-345-6169
Employees: 1,554
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $35.00
High Stock Price Forecast: $35.00
Low Stock Price Forecast: $35.00
Forecasted Upside/Downside: -7.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.57
Trailing P/E Ratio: 66.65
Forward P/E Ratio: 39.57
P/E Growth: N/A
Net Income: $25.44 million
Net Margins: 3.72%
Pretax Margin: 4.80%
Return on Equity: 1.52%
Return on Assets: 1.24%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.36
Quick Ratio: 2.83

Sales & Book Value

Annual Sales: $572.95 million
Price / Sales: 2.49
Cash Flow: $1.71 per share
Price / Cash Flow: 22.22
Book Value: $46.05 per share
Price / Book: 0.82

Miscellaneous

Outstanding Shares: 37,580,000
Free Float: 32,398,000
Market Cap: $1.43 billion
Optionable: Optionable
Beta: 0.60

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Uday V. Baldota (Age 53)
CEO & Director

Mr. William J. Coote (Age 68)
VP, CFO & Chief Accounting Officer

Mr. Itamar Karsenti (Age 51)
VP & Head of Operations

Mr. Avi Avramoff (Age 58)
VP and Head of R&D

Mr. Itzik Baruch (Age 60)
VP of Technical Services

Dr. Roman Kaplan (Age 76)
VP of Scientific and Technical Compliance Mang.

Mr. Erik Zwicker J.D. (Age 43)
VP, Gen. Counsel & Sec.

Mr. Ara Aprahamian (Age 55)
VP of Sales & Marketing
Comp: $616.14k

Ms. Michele Visosky (Age 57)
VP & Head of Human Resource

Mr. Jayesh Shah (Age 67)
Head of Procurement

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

TARO Stock - Frequently Asked Questions

Should I buy or sell Taro Pharmaceutical Industries stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TARO shares.
View TARO analyst ratings or view top-rated stocks.
What is Taro Pharmaceutical Industries' stock price forecast for 2023?: 1 brokers have issued 12 month target prices for Taro Pharmaceutical Industries' shares. Their TARO share price forecasts range from $35.00 to $35.00. On average, they predict the company's share price to reach $35.00 in the next twelve months. This suggests that the stock has a possible downside of 7.9%.
View analysts price targets for TARO or view top-rated stocks among Wall Street analysts.
How have TARO shares performed in 2023?: Taro Pharmaceutical Industries' stock was trading at $29.04 at the beginning of the year. Since then, TARO stock has increased by 30.8% and is now trading at $37.99.
View the best growth stocks for 2023 here.
Are investors shorting Taro Pharmaceutical Industries?: Taro Pharmaceutical Industries saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 398,600 shares, an increase of 82.5% from the August 15th total of 218,400 shares. Based on an average trading volume of 64,200 shares, the short-interest ratio is presently 6.2 days. Currently, 4.9% of the shares of the stock are sold short.
View Taro Pharmaceutical Industries' Short Interest.
When is Taro Pharmaceutical Industries' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our TARO earnings forecast.
How were Taro Pharmaceutical Industries' earnings last quarter?: Taro Pharmaceutical Industries Ltd. (NYSE:TARO) issued its earnings results on Wednesday, July, 26th. The company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.09. The firm earned $158.89 million during the quarter, compared to analysts' expectations of $149 million. Taro Pharmaceutical Industries had a trailing twelve-month return on equity of 1.52% and a net margin of 3.72%.
What ETF holds Taro Pharmaceutical Industries' stock ?: ARK Israel Innovative Technology ETF holds 58,404 shares of TARO stock, representing 2.19% of its portfolio.
What is Uday Baldota's approval rating as Taro Pharmaceutical Industries' CEO?: 11 employees have rated Taro Pharmaceutical Industries Chief Executive Officer Uday Baldota on Glassdoor.com. Uday Baldota has an approval rating of 19% among the company's employees. This puts Uday Baldota in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Taro Pharmaceutical Industries own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Broadcom (AVGO), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), GW Pharmaceuticals (GWPH), Delta Air Lines (DAL), Jazz Pharmaceuticals (JAZZ) and Southwest Airlines (LUV).
What is Taro Pharmaceutical Industries' stock symbol?: Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."
Who are Taro Pharmaceutical Industries' major shareholders?: Taro Pharmaceutical Industries' stock is owned by a number of retail and institutional investors. Top institutional investors include Krensavage Asset Management LLC (1.71%), Renaissance Technologies LLC (1.58%), BlackRock Inc. (1.55%), Dimensional Fund Advisors LP (1.47%), Acadian Asset Management LLC (0.66%) and Hotchkis & Wiley Capital Management LLC (0.59%).
How do I buy shares of Taro Pharmaceutical Industries?: Shares of TARO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Taro Pharmaceutical Industries' stock price today?: One share of TARO stock can currently be purchased for approximately $37.99.
How much money does Taro Pharmaceutical Industries make?: Taro Pharmaceutical Industries (NYSE:TARO) has a market capitalization of $1.43 billion and generates $572.95 million in revenue each year. The company earns $25.44 million in net income (profit) each year or $0.57 on an earnings per share basis.
How many employees does Taro Pharmaceutical Industries have?: The company employs 1,554 workers across the globe.
How can I contact Taro Pharmaceutical Industries?: Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The official website for the company is www.taro.com. The company can be reached via phone at (724) 847-5700, via email at investorrelations@taro.com, or via fax at 914-345-6169.

This page (NYSE:TARO) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial